China vs Mus: New or unknown treatment: Pulmonary, bacteriologically confirmed
China
326,625
in 2023
Mus
99
in 2023
China rank
3rd
Mus rank
1st
New or unknown treatment: Pulmonary, bacteriologically confirmed over time
- China
- Mus
How they compare
China currently reports 326,625 against 99 in Mus, a difference of 326,526.
That makes China's figure about 3,299.2 times Mus's.
Across all 11 years both countries report, China has been ahead every year.
China ranks 3rd and Mus ranks 1st of 197 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 241,700 | 113.57 | 241,586 | China |
| 2020s | 297,397 | 94.5 | 297,302 | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher new or unknown treatment history cases: pulmonary, bacteriologically, China or Mus?
- China, at 326,625 against 99 in Mus as of 2023.
- What is the difference in new or unknown treatment history cases: pulmonary, bacteriologically between China and Mus?
- 326,526, with China ahead.
- How many years of comparable data are there for China and Mus?
- 11 years are reported by both, from 2013 to 2023.
- How do China and Mus rank globally for new or unknown treatment history cases: pulmonary, bacteriologically?
- China ranks 3rd and Mus ranks 1st of 197 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as New or unknown treatment history cases: Pulmonary, bacteriologically confirmed. Statizoid refreshes it automatically from the source and publishes the full history for both places.